Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33

Angela J Okragly, Katie Brannon Corwin, Marikka Elia, Dongmei He, Oliver Schroeder, Qing Zhang, Tatiyana Shiyanova, Stuart Bright, Sarah B Dicker, Lukasz Chlewicki, Stephanie ME Truhlar, Julian Davies, Chetan N Patel, Robert J Benschop

1Immunology Research, Eli Lilly and Company, Indianapolis, IN, USA; 2BioTechnology Discovery Research, Eli Lilly and Company, Indianapolis, IN, USA; 3BioTechnology Discovery Research Eli Lilly and Company, San Diego, CA, USA; 4ADME, Eli Lilly and Company, Indianapolis, IN, USA

Background: Interleukin-33 (IL-33) is an alarmin that is released following cellular damage, mechanical injury, or necrosis. It is a member of the IL-1 family and binds to a heterodimer receptor consisting of ST2 and IL-1RAP to induce the production of a wide range of cellular mediators, including the type 2 cytokines IL-4, IL-5 and IL-13. This relationship has led to the hypothesis that the IL-33/ST2 pathway is a driver of allergic disease and inhibition of the IL-33 and ST2 association could have therapeutic benefit.

Methods: In this paper, we describe the selection of a phage antibody through the ability to bind human IL-33 and block IL-33/ST2 interaction. This hit antibody was then affinity matured by site-directed mutagenesis of the antibody complementarity-determining regions (CDRs). Further characterization of a fully human monoclonal antibody (mAb), torudokimab (LY3375880) included demonstration of human IL-33 neutralization activity in vitro with an NFκB reporter assay and IL-33 induced mast cell cytokine secretion assay, followed by an in vivo IL-33-induced pharmacodynamic inhibition assay in mice that used IL-5 production as the endpoint.

Results: Torudokimab is highly specific to IL-33 and does not bind any of the other IL-1 family members. Furthermore, torudokimab binds human and cynomolgus monkey IL-33 with higher affinity than the binding affinity of IL-33 to ST2, but does not bind mouse, rat, or rabbit IL-33. Torudokimab’s half-life in cynomolgus monkey projects monthly dosing in the clinic.

Conclusion: Due to torudokimab’s high affinity, its ability to completely neutralize IL-33 activity in vitro and in vivo, and the observed cynomolgus monkey pharmacokinetic properties, this molecule was selected for clinical development.

Keywords: IL-33, Th2 immune response, monoclonal antibody

Introduction

IL-33 is a member of the IL-1 cytokine family that includes IL-1α, IL-1β, and IL-181 and is constitutively expressed in structural and lining cells including fibroblasts, endothelial, and epithelial cells of skin, gastrointestinal tract, and lungs.2-4 Full-length IL-33 contains a chromatin binding domain that results in nuclear localization.5,6 IL-33 is released in its full-length form after cellular damage, mechanical injury, or necrosis, thus functioning as an alarmin. The full-length IL-33 is cleaved into a mature cytokine form by a variety of proteases.4,7,8 The effects of IL-33 are mediated through its interaction with a heterodimeric receptor consisting of membrane-bound ST2 (also known as IL1RL1) and IL-1RAP, leading to NFκB and MAPK activation.9,10 Binding of IL-33 to its receptor activates T cells,1,11
basophils,12 mast cells,13 eosinophils,14 type 2 innate lymphoid cells (ILC2),15,16 dendritic cells,17 endothelial cells and epithelial cells,18 causing the production of numerous pro-inflammatory mediators.

IL-33 induces the production of canonical type 2 cytokines, IL-4, IL-5 and IL-13.1,12 These type 2 downstream mediators can give rise to many of the hallmarks of allergic response such as increase in IgE production, increase in eosinophil migration into allergic inflammatory tissues, mucus production, airway hyperresponsiveness, etc. that drives disease pathology.19–21 Atopic dermatitis is one of the most common chronic inflammatory skin diseases and its pathogenesis includes impaired skin barrier function, excess type 2 cytokine production and severe pruritus.22,23 In association studies, genes encoding IL-33 and its receptors have been identified as susceptibility loci in allergic disease.24–30 In humans, both IL-33 mRNA and protein are substantially elevated in the inflamed skin lesions of patients with atopic dermatitis when compared with non-inflamed skin.31 In addition, IL-33 is a chemoattractant for both T helper type 2 (Th2) and ILC2, which are enriched in human atopic dermatitis lesions.32,33 In mice, skin-specific expression of IL-33 has been shown to activate ILC2 cells, elicit allergic skin inflammation and scratching behavior,34 and it has been demonstrated that IL-33/ST2 signaling excites sensory neurons and mediates itch response.35 Together, these data suggest that IL-33 could be an important component in the pathogenesis of atopic dermatitis.

Because IL-33 is an alarmin, acts locally at the sites of inflammation and is upstream of the canonical type 2 cytokines, its neutralization may have the potential for efficacy in patients with allergic diseases. Therefore, the development of a neutralizing antibody recognizing human IL-33 was undertaken resulting in torudokimab, which began a first-in-human study in November 2017 (NCT03343587) and a Phase 2 study in atopic dermatitis in February 2019 (NCT03831191) to test the hypothesis that IL-33 neutralization could be of therapeutic use in atopic dermatitis and other allergic diseases. This report describes the generation and characterization of torudokimab (LY3375880), a fully human IL-33-neutralizing antibody.

Materials and Methods

IL-33, ST2 and Antibody Expression and Purification

Recombinant IL-33 ligands were expressed and purified from E. coli cells in-house. Human IL-33 (UniProt #O95760) was expressed as both Thr90-Thr270 and Ala95-Thr270 fragments representing the cleaved mature form of IL-33. Mouse (UniProt #Q8BVZ5) and rat (UniProt #Q66H70) IL-33 ligands were generated as Ala102-Ile266 and Ser109-Met264 fragments, respectively. The sequences for cynomolgus monkey and rabbit IL-33 were not available, so the Rapid Amplification of cDNA Ends (RACE) method was used to obtain the coding sequences for cynomolgus monkey IL-33 and rabbit IL-33 from cynomolgus monkey brain cDNA and rabbit brain cDNA, respectively. From the resulting clones, recombinant rabbit IL-33 (Ala101-Ser254) and cynomolgus monkey IL-33 (Ala95-Ile270) were also expressed and purified.

Recombinant monomeric human ST2 was produced in-house. First, a mammalian expression plasmid was generated encoding the extracellular domain of human ST2 (Lys19-Ser328, UniProt #Q01638), a FactorXa cleavage site, and a C-terminal human IgG4 Fc. The ST2-Xa-Fc fusion protein was expressed transiently in Human Embryonic Kidney 293 cells (HEK293) (ATCC, Manassas, VA, USA) and purified by Protein A and preparative size-exclusion chromatography (SEC). The resulting dimeric Fc fusion protein was treated with Factor Xa enzyme resulting in the cleavage of the Fc. The digested material was incubated with Xarrest Agarose (EMD Millipore, #69038) to bind and remove Factor Xa enzyme and then passed over a Protein A column again. Unbound protein was collected and polished by preparative SEC. The resulting human ST2 protein was characterized as a monomer by SDS-PAGE and analytical SEC.

Discovery antibodies were expressed in HEK293 or Chinese Hamster Ovary (CHO) cells (Lonza, Morristown, NJ, USA) using mammalian expression vectors encoding the respective light chain and heavy chain. The antibodies were bound to Protein A resin and eluted using low pH buffer. The eluted antibody was further purified using preparative SEC or cation exchange chromatography (CEX) as a polishing step. Antibody purity was evaluated by SDS-PAGE, analytical SEC-HPLC, and LC/MS analysis. Endotoxin was <1 EU/mg as measured by the Endosafe® PTS (Charles River Laboratories, Wilmington, MA, USA). Purified antibodies were buffer exchanged in phosphate-buffered saline (PBS), pH 7.2 and stored at 4°C. An IgG4 isotype control antibody was generated using a similar method.
Analytical Assays
Analytical Heparin Binding Chromatography Assay
Twenty mg of IgG samples (1 mg/mL) in PBS was injected onto a HiTrap Heparin HP 1 mL column (GE Healthcare, #17-0406-01). Flow was kept at 1.0 mL/min with an initial linear gradient up to 2% B in 3 minutes, then up to 100% B in an additional 40 minutes. Gradient was left at 100% B for an additional 5 minutes to remove any remaining protein. Column was re-equilibrated at 100% A for 5 minutes prior to the next injection.

Analytical Hydrophobicity Interaction Chromatography Assay
Twenty mg IgG samples (1 mg/mL) were diluted 1:1 with 2x Buffer A concentrate (2 M ammonium sulfate, 0.1 M sodium phosphate at pH 6.8) to achieve a final ammonium sulfate concentration of 1 M before analysis. A TSKgel butyl-NPR column (4.6mm ID x 10cm, 2.5um, Tosoh #42168) was used with a linear gradient (0–100% B) of mobile phase A (1 M ammonium sulfate, 50 mM sodium phosphate, pH 6.8) and mobile phase B solution (50 mM sodium phosphate, pH 6.8) over 23 min at a flow rate of 1 mL/min with UV absorbance monitoring at 280 nm.

Antibody Discovery
To generate antibodies specific to human IL-33, a phage display library displaying fully human Fabs was panned with soluble human IL-33 for three rounds. Positive phage bearing IL-33-binding Fabs were isolated using standard procedures. These were then expressed as a kappa light chain and human IgG4 variant heavy chain (IgG4-PAA) sequence was removed to reduce chemical heterogeneity during expression. Antibodies were screened for binding to human IL-33 by ELISA. From this library, three framework variants (LSN3330868, LSN3348360, LSN3348361) were selected and further characterized by transient CHO expression titer and analytical assays. LSN3348360 (3–53 heavy chain human framework and A27 human light chain framework) was chosen for further development and optimized for binding to cynomolgus monkey IL-33. To accomplish this, the CDRs of the isolated VH and VL of LSN3348360 were randomized by mutagenesis and resulting antibodies screened for binding to human IL-33 and cynomolgus monkey IL-33 by filter lift and ELISA. Affinity enhancing mutations to cynomolgus monkey IL-33 which did not significantly impact affinity to human IL-33 were then combined to yield LSN3358818 which was then further engineered to reduce potential immunogenicity, which resulted in torudokimab (LY3375880). The clinical candidate was expressed in CHO and purified as described above.

Blocking Assay
Antibodies to IL-33 were used in a blocking ELISA assay to determine their ability to block human IL-33 (90–270) binding to human ST2. Briefly, an ELISA plate coated with 50ul of goat anti-human IgG1 antibody (Jackson ImmunoResearch Laboratories, #109-005-098) at 1ug/mL was used to capture 50ul of human ST2-Fc (R&D Systems, #523-ST-100) at 1 mg/mL following incubation for 1 hour at room temperature. Torudokimab and the corresponding isotype control antibody were then titrated and pre-incubated for 1 hour at room temperature with a fixed concentration of biotinylated IL-33 before incubating in the ELISA plate for 20 minutes at room temperature. After washing the plate, bound biotinylated IL-33 was detected using Alkaline phosphatase labelled Neutravidin (ThermoFisher Scientific, #31002).

Affinity enhancing mutations were then combined to yield LSN3330868 which was then optimized using a framework library approach. For the framework library, twelve human VH framework germline genes (1–24, 1–46, 1–69, 2–5, 3–15, 3–23, 3–53, 3–72, 4–04, 4–39, 5–51, and 6–01) and eight human VL framework genes (A-19, A-26, A-27, B-2, B-3, L-2, L-12, and O-2) containing LSN3380868 CDRs were synthesized, cloned into heavy and light chain human IgG4-PAA expression vectors, expressed in HEK293, and subsequently screened for binding to human IL-33 by ELISA. From this library, three framework variants (LSN3330868, LSN3348360, LSN3348361) were selected and further characterized by transient CHO expression titer and analytical assays. LSN3348360 (3–53 heavy chain human framework and A27 human light chain framework) was chosen for further development and optimized for binding to cynomolgus monkey IL-33. To accomplish this, the CDRs of the isolated VH and VL of LSN3348360 were randomized by mutagenesis and resulting antibodies screened for binding to human IL-33 and cynomolgus monkey IL-33 by filter lift and ELISA. Affinity enhancing mutations to cynomolgus monkey IL-33 which did not significantly impact affinity to human IL-33 were then combined to yield LSN3358818 which was then further engineered to reduce potential immunogenicity, which resulted in torudokimab (LY3375880). The clinical candidate was expressed in CHO and purified as described above.
Binding Affinity and Specificity

The binding kinetics and affinity of torudokimab to human, cynomolgus monkey, mouse, rat, and rabbit IL-33 were determined using a surface plasmon resonance (SPR) assay on either a Biacore T100 or T200 instrument primed with HBS-EP+ (10 mM Hepes pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20, GE Healthcare Life Sciences, Marlborough, MA, USA) running buffer and analysis temperature set at 37°C. A CM4 chip containing immobilized Protein A (generated using standard NHS-EDC amine coupling) on all four flow cells was used to employ a capture method. Antibody samples were prepared at 10 µg/mL by dilution into running buffer. Mouse, rat, and rabbit IL-33 samples were prepared at final concentrations of 1000, 500, 250, 125, 63, 31, 16, and 0 (blank) nM by dilution into running buffer. Human and cynomolgus IL-33 samples were prepared at final concentrations of 250, 125, 63, 31, 16, 8, 4, 2, 1, and 0 (blank) nM by dilution into running buffer. A fresh, single-use aliquot of IL-33 was used for each replicate experiment to prevent multiple freeze-thaw cycles. Data were processed using standard double referencing and fit to a 1:1 binding model using Biacore Evaluation software (version 2.0.1), to determine the association rate (on-rate, $k_{on}$, $M^{-1}s^{-1}$ units) and the dissociation rate (off-rate, $k_{off}$, $s^{-1}$ units). The equilibrium dissociation constant ($K_D$) was calculated from the relationship $K_D = k_{off}/k_{on}$ and is in molar units. Three experimental replicates (n) were conducted for the binding of torudokimab to human and cynomolgus monkey IL-33. To assess binding affinity to human IL-1α, IL-1β (PeproTech, Inc., Rocky Hill, NJ, USA), IL-18 (MBL International, Woburn, MA, USA), IL-1RA, IL-36α, IL-36β, IL-36γ, IL-36Ra, IL-37 (R&D Systems, Minneapolis, MN, USA) torudokimab was tested at concentrations up to 500 nM by using this same basic procedure.

Cell-Based Neutralization Assays

Luciferase Reporter Assay

Human glomerular endothelial cell (GEC) line (Applied Cell Biology Research Institute, Kirkland, WA, USA) transfected with NFκB-Luciferase (NFκB-Luc) (generated in-house) were routinely cultured in assay medium (EGM™ BulletKit™ medium (LONZA, Basel, Switzerland) plus puromycin). On the day prior to the assay, confluent GEC-NFκB-Luc cells were removed with trypsin, spun down, washed and resuspended in fresh media. The cells were plated in triplicate for biological replicates at 5000 cells in 50 µL/well in a white walled collagen I treated plate (BD BioCoat™, BD Biosciences, NJ, USA), and the plate was incubated overnight. The next day the cells were treated with torudokimab in the presence of 2.5ng/mL cleaved mature form IL-33 from different species (in-house). A dose range of torudokimab from 0 to 133.3 nM was evaluated. Human monomeric ST2 (in-house) was used as a positive control in the assay and an isotype control antibody (in-house) was used as the negative control. Testing was done in triplicates. The 96-well plates were placed in tissue culture incubator (37°C, 95% relative humidity, 5% CO₂) for 4 hours. Then, 100 µL/well of ONE-Glo™ Luciferase solution (Promega, Madison, WI, USA) was added to measure luciferase activity. A luminometer (VICTOR, Perkin Elmer, Waltham, MA, USA) was used to read the plates.

Mast Cell Cytokine Secretion Assay

Human mast cells were differentiated in culture from human cord blood stem cells (StemCell Technologies, Vancouver, Canada) using StemSpan™ media (StemCell Technologies, Vancouver, Canada) and human stem cell factor (SCF)/IL-6. On the day of the assay, mast cells were collected from the flasks, centrifuged at 200 g for 5 min, and re-suspended in fresh media. The cells were plated in triplicate for biological replicates at 50,000 cells in 50 µL/well in 96-well tissue culture plate and treated with 10ng/mL cleaved mature form of human IL-33 in the presence/absence of different antibodies. A dose range of torudokimab from 0 to 30 nM was evaluated. The assay medium alone was used for “no treatment” control. Human monomeric ST2 was used as positive control in the assay and an isotype control antibody was used as the negative control. Testing was done in triplicate. The 96-well plates were placed in tissue culture incubator (37°C, 95% relative humidity, 5% CO₂) for 16 hours. Supernatant of 100 µL/well was collected to measure GM-CSF levels by ELISA (R&D Systems, Minneapolis, MN, USA) according to manufacturer’s instructions.

Ethical Use of Animals

The use of mice and cynomolgus monkeys followed the ethical guidelines stated in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Animal study protocols were approved by Lilly Animal Policy and Welfare Committee.
Pharmacodynamic Assay in Mice

C57BL/6 mice (n=5) were injected intraperitoneally with 0.94 mg/kg, 0.282 mg/kg or 0.094 mg/kg (10-fold, 3-fold or equimolar amounts relative to human IL-33 (95–270), respectively) of torudokimab or with an isotype control antibody at 0.94 mg/kg (10-fold relative to human IL-33). One day post-injection, mice were challenged by intraperitoneal injection of 0.025 mg/kg of human IL-33 (95–270). Six hours post-human IL-33 challenge, mice were sacrificed, and serum was collected. Serum was analyzed for levels of mouse IL-5 using a commercial ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

Single Dose Pharmacokinetics in Cynomolgus Monkey

The pharmacokinetics (PK) of torudokimab was characterized in male cynomolgus monkeys following a single intravenous (IV) bolus or subcutaneous (SC) administration of 5 mg/kg with two monkeys per group. Blood samples were collected from the femoral vein prior to dosing and at 1, 6, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, and 672 hours after administration. The blood samples were allowed to clot at ambient temperature prior to centrifugation to obtain serum. Serum concentrations were determined using an IL-33 antigen capture or total human IgG ELISA. The standard curve range was 7.8–500 ng/mL with an upper limit of quantitation (ULOQ) at 200 ng/mL and a lower limit of quantitation (LLOQ) at 12.5 ng/mL. PK parameters were determined via non-compartmental analysis using Phoenix® (WinNonlin®). Cross-reactivity was assessed using aHeparin (Relative Binding) and aHIC (Relative Binding) to determine the relative hydrophobicity, and binding affinity (Kd) of the lead antibody (LSN3348360) and binding affinity (Kd) of the lead antibody (LSN3348360) to LSN3330868 (3–23/A27) and LSN3348361 (3–53/L12) variants in transient CHO resulted in higher titers as compared to LSN3330868 (3–23/A27).

Results

Antibody Engineering and Affinity Determination

The IL-33 Antibody 23 discovered from the phage library had a low affinity (21.9 nM) contained 3–23 (VH) and A27 (VK) germlines and had eight non-germline somatic hypermutations in the framework regions of the VK domain. Affinity maturation of Antibody 23 to enhance binding to human IL-33 and reverting framework somatic hypermutations resulted in Antibody LSN3330868 which bound human IL-33 with an affinity of 34 pM and cynomolgus monkey IL-33 with an affinity of 9.6 nM. Further, engineering using framework library shuffling resulted in Antibody LSN3348360 containing 3–53 and A27 germlines that bound to human IL-33 with an affinity of 14.5 pM and bound to cynomolgus monkey IL-33 with an affinity of 12.4 nM, representing an ~850-fold difference in species cross-reactivity. The expression of the framework optimized LSN3348360 (3–53/A27) and LSN3348361 (3–53/L12) variants in transient CHO resulted in higher titers as compared to LSN3330868 (3–23/A27). Analytical hydrophobic interaction chromatography (aHIC) was used to determine the relative hydrophobicity. Analytical heparin-binding chromatography (aHeparin) was used to determine the relative heparin-binding profile. All three framework variants had low hydrophobility, but LSN3348360 exhibited reduced nonspecific binding to Heparin compared to LSN3330868 and LSN3348316. These data are summarized in Table 1. Based on this profile, LSN3348360 was identified as the lead antibody. LSN3348360 was then optimized for binding to cynomolgus monkey IL-33. This antibody bound to human IL-33 with an affinity of 46 pM and bound to cynomolgus monkey IL-33 with an affinity of 217 pM representing a 5-fold difference in species cross-reactivity. LSN3358818 was then further engineered to reduce potential immunogenicity, which resulted in the clinical candidate antibody LY3375880 (torudokimab).

To characterize the binding kinetics of torudokimab to different IL-33 species and assess binding to members of the IL-1 family, we used Biacore. Table 2 summarizes the association rate (k_a) in aHIC (Relative Binding), the dissociation rate (k_d), and binding affinity (K_d) of the lead antibody (LSN3348360) and torudokimab to various IL-33 ligands. Torudokimab bound to human and cynomolgus monkey IL-33 (95–270) with binding affinities (K_d) of 49 pM and 338 pM, an improved ~7X differential compared to LSN3348360, which has

Table 1

Characterization of Framework Library Antibody Variants. Relative Binding for Each Analytical Assay Was Evaluated as Follows: Low Binding (+), Moderate Binding (++), High Binding (+++)
a ~850X species differential and lacked binding to mouse, rat, and rabbit IL-33 (KD >1000 nM) (Table 2). The individual binding sensorgrams for LSN3348360 and torudokimab to both human and cynomolgus monkey IL-33 (95–270) are shown in Figure 1.

It was confirmed that torudokimab could inhibit the binding of 30ng/mL IL-33 (95–270) to ST2 with an IC50 of 3.7nM (Figure 2A). The engineering of human and cynomolgus monkey cross-reactivity was needed to enable downstream non-human primate toxicity studies. Torudokimab did not bind to other members of the human IL-1 family at a concentration of 500 nM (IL-1α, IL-1β, IL-18, IL-1RA, IL-36α, IL-36β, IL-36γ, IL-36Ra), while antibodies used as positive controls to each family member were able to bind specifically to each cytokine (data not shown).

### Cell-Based IL-33 Neutralization Assays

A human GEC NFκB-luciferase cell line naturally expresses ST2 and its co-receptor IL1RAP and was used to measure the ability of IL-33 antibodies to inhibit the activation of the NFκB pathway by IL-33. As shown in

---

**Figure 1** SPR sensorgrams for the binding kinetics of LSN3348360 and torudokimab to human (95–270) and cynomolgus (95–270) monkey IL-33 at 37°C. The engineering of LSN3348360 to produce torudokimab resulted in improved binding to cynomolgus monkey IL-33. Antibodies were captured on the surface of a CM4 chip with immobilized Protein A and different concentrations of IL-33 were injected to assess binding kinetics. Double reference subtracted binding sensorgrams are shown.

---

**Table 2** Binding Kinetics and Affinity of IL-33 Monoclonal Antibodies at 37°C

| Antibody      | Antigen                  | \( k_{on} \) (M\(^{-1}\)s\(^{-1}\)) Avg±SD | \( k_{off} \) (s\(^{-1}\)) Avg±SD | \( K_D \) (pM) Avg±SD | N  |
|---------------|--------------------------|--------------------------------------------|---------------------------------|------------------------|----|
| LSN3348360    | Human IL-33 (95–270)     | 1.7±0.5 x 10\(^6\)                         | 2.6±0.1 x 10\(^{-5}\)          | 14.5±1.5               | 3  |
| LSN3348360    | Cynomolgus IL-33 (95–270)| 1.7±0.6 x 10\(^6\)                         | 1.9±0.1 x 10\(^{-2}\)          | 12,400±4000            | 3  |
| Torudokimab   | Human IL-33 (95–270)     | 1.5±0.1 x 10\(^6\)                         | 7.2±1.7 x 10\(^{-5}\)          | 49±14                  | 3  |
| Torudokimab   | Cynomolgus IL-33 (95–270)| 1.5±0.2 x 10\(^6\)                         | 5±2.0 x 10\(^{-5}\)           | 338±45                 | 3  |
| Torudokimab   | Mouse IL-33 (102–266)    | K\(_D\) > 1000 nM                          |                                 |                        | 1  |
| Torudokimab   | Rat IL-33 (109–264)      | K\(_D\) > 1000 nM                          |                                 |                        | 1  |
| Torudokimab   | Rabbit IL-33 (101–254)   | K\(_D\) > 1000 nM                          |                                 |                        | 1  |

**Note:** Error is reported as the standard deviation (SD).
Figure 2B, torudokimab inhibited human- and cynomolgus monkey-, but not mouse-, rat- or rabbit-IL33-induced NFκB activity in a dose-dependent manner. The average (+SD) IC_{50} (half maximal inhibitory concentration) from three independent experiments run in triplicate showed that torudokimab inhibited human IL-33 (95–270) at 0.330 ± 0.112 nM and cynomolgus monkey IL-33 (95–270) at 1.918 ± 0.152 nM. Whereas soluble ST2 (sST2), the positive control, inhibited human IL-33 at 0.426 ± 0.115 nM and cynomolgus monkey IL-33 at 0.175 ± 0.021 nM. The negative control antibody did not inhibit NFκB activity in GEC-NFκB-luc cells at any concentration tested.

Human mast cells naturally express the ST2 receptor and its co-receptor IL1RAP and their response to human IL-33 results in cytokine secretion. In preliminary studies, IL-33
induced the production of several cytokines including IL-5, IL-13, IL-8, IL-10 and GM-CSF (data not shown). GM-CSF was the mediator selected as an exemplar cytokine to determine whether torudokimab was able to inhibit IL-33 activation of primary human cells due to the consistency and magnitude of the GM-CSF response. As shown in Figure 3, torudokimab completely inhibited the cleaved mature form of human IL33-induced GM-CSF secretion from human mast cells in a dose-dependent manner. The isotype control antibody did not inhibit IL-33 induced GM-CSF secretion. Results are representative of two independent experiments.

**Pharmacodynamic Assay in Mice**

To determine neutralization of IL-33 in vivo we used a pharmacodynamic model in the mouse. Previous work demonstrated that intraperitoneal injection of human IL-33 into a mouse induced the production of mouse IL-5, which can readily be measured in serum. IL-5 was selected as the representative cytokine for the pharmacodynamic model due to the reproducibility of the response following a single injection of IL-33. Torudokimab at 3 different doses or an isotype control Ab was administered 1 day prior to injection of the IL-33 stimulus. Six hours later, mouse serum was collected and analyzed for IL-5 levels. As shown in Figure 4, torudokimab was able to completely inhibit the IL-33-driven increase of mouse IL-5 in a dose dependent manner. The isotype control antibody did not inhibit the human IL-33-induced increase in mouse IL-5. These data demonstrate that torudokimab neutralizes human IL-33 in vivo.

**Single-Dose Pharmacokinetics in Monkeys**

Single-dose PK of torudokimab was characterized in male cynomolgus monkeys (Figure 5). Elimination rate was typical of an IgG4 antibody. The mean clearance of torudokimab, estimated by total IgG ELISA, was approximately 0.21 mL/hr/kg for the IV dose group with complete bioavailability following SC route administration (Table 3). The mean terminal half-life following IV administration was estimated to be approximately 250 to 280 hours (Table 3). PK profiles following SC or IV administration did not suggest an impact of anti-drug antibodies, if present, on torudokimab exposures. Overall, torudokimab exhibited favorable PK properties, supporting monthly dosing in humans.

**Discussion**

IL-33 plays many roles in both tissue homeostasis and driving innate and adaptive inflammatory responses in a wide variety of barrier tissue. It is widely known as a driver of allergic responses through the excess activation of mast cells, basophils, and ILC2 cells leading to increased cell migration and the production of canonical Th2 cytokines. Mast cells can be used as an example of the strong biological effects of IL-33 due to their high levels of ST2 expression. IL-33 has been shown to induce a larger release of cytokines and chemokines from human mast cells than TSLP. Additionally, IL-33 can potentiate IgE induced human mast cell degranulation and drive individual mast cells to a higher magnitude of degranulation. Due to the
profound biological effects of IL-33, nature has devised multiple endogenous mechanisms to regulate IL-33 activity including binding to soluble form of ST2 receptor that circulates at relatively high levels, inactivation by oxidation at cysteine residues, and protease cleavage and degradation by neutrophil and mast cell enzymes. These
multiple mechanisms to control levels of active IL-33 imply that it is important to regulate IL-33 activity to prevent immune-hyper-reactivity. As such, we hypothesized that additional control over the IL-33/ST2 signaling pathway would be beneficial in some disease states and this idea drove us to develop a high affinity neutralizing IL-33 mAb that completely inhibited the IL-33/ST2 interaction.

Our data demonstrate that we were able to develop a fully human mAb that completely neutralizes human IL-33 activity. The lead molecule bound to human IL-33 with an affinity of 14.5 pM, tighter than the 450 pM IL-33:ST2 affinity previously reported in the literature. However, it had a 12,400 pM affinity to cynomolgus monkey IL-33, representing an ~850-fold difference in species cross-reactivity (Table 2). This difference was seen despite 94% sequence identity between human and cynomolgus monkey IL-33. Additional affinity maturation against the cynomolgus monkey IL-33 along with further engineering to reduce potential immunogenicity, resulted in the molecule chosen for further clinical development, torudokimab. Torudokimab binds to human IL-33 with an affinity of 49 pM and to cynomolgus monkey IL-33 with an affinity of 338 pM, representing an ~7-fold difference in species cross-reactivity (Table 2). These affinity measurements were performed at 37°C, to understand physiologically relevant binding; we do not know the temperature used to determine the affinity between human IL-33 and ST2 of 450 pM (ref 42), but even so, torudokimab binds much tighter to IL-33 than IL-33 binds to ST2, making it a highly competitive mAb.

Torudokimab does not bind to mouse, rat or rabbit forms of IL-33 nor does it bind to any of the other IL-1 family members (Table 2). Additionally, torudokimab was able to completely inhibit IL-33 interaction with ST2 (Figure 2A), neutralize human IL-33 activity in in vitro cell-based assays as shown by the inhibition in the GEC-NFκB reporter assay and the blockade of GM-CSF secretion from human mast cells (Figure 2B) with a greater potency than the sST2 positive control. This demonstrates that torudokimab is a better competitive agent than sST2, consistent with the higher affinity of torudokimab to IL-33 compared to IL-33 to ST2. In an in vivo mouse model of human IL-33 activity as measured by serum IL-5 levels, torudokimab completely inhibited the IL-5 production (Figure 4). Together, the data demonstrate that torudokimab is a highly potent, selective inhibitor of human IL-33 activity.

There are three major therapeutic strategies for blocking the binding of IL-33 to ST2 – optimized soluble decoy receptors, ST2 neutralizing antibodies or IL-33 neutralizing antibodies. Our team decided against pursuing the soluble decoy
receptor strategy due to the difficulty in developing a stable molecule with a sufficiently long clinical half-life. ST2 is highly expressed in multiple cell types including both immune cells and stromal cells. Additionally, soluble ST2 is found in the ng/mL range in serum and is often elevated due to disease. Due to the high amount of target represented by the receptor and soluble forms of ST2, we decided to focus our efforts on developing a neutralizing IL-33 mAb, which is only observed at low levels in circulation. Out of the several ST2 and IL-33 monoclonal antibodies in clinical development, others including Roche and GSK decided to develop ST2 neutralizing monoclonal antibodies, which are currently in clinical trials for atopic dermatitis and respiratory diseases. Several other companies are developing IL-33 monoclonal antibodies including Sanofi with studies in atopic dermatitis and asthma; AstraZeneca in clinical studies of atopic dermatitis, chronic obstructive pulmonary disease (COPD), diabetic kidney disease and COVID-19, and Mitsubishi Tanabe Pharma is pursuing allergic rhinitis and endometrial related pain as indications. While most of these studies are focused on allergic disease, it is interesting to consider other possibilities for IL-33/ST2 axis inhibitors. Besides driving a type 2 immune response, IL-33 acts on multiple cell types and can induce other cytokines that are associated with autoimmunity, such as TNFa, IL-1b, IL-6, and GM-CSF along with several chemokines. Additionally, genetic polymorphism of IL-33 and ST2 have been linked to inflammatory-bowel disease, COPD, systemic sclerosis, rheumatoid arthritis and systemic lupus erythematosus. These associations suggest there could be a therapeutic role for IL-33 inhibition in multiple inflammatory and autoimmune diseases.

Conclusion
In conclusion, this study described the discovery and preclinical evaluation of torudokimab, a human IgG4PAA mAb with high affinity and specificity for IL-33. Its high binding affinity to IL-33 translates to complete neutralization of IL-33-mediated biological activities in vitro and in vivo. Torudokimab has progressed into a clinical study of atopic dermatitis.

Ethics Approval and Informed Consent
All mice were housed and maintained at Eli Lilly and Company (Indianapolis, IN) in accordance with the research guidelines of the Institutional Animal Care and Use Committee. Cynomolgus monkeys in the sponsor’s stock colony maintained at Covance are maintained and monitored for good health in accordance with Covance SOPs and at the discretion of the laboratory animal veterinarian. Prior to assignment to the study, the health of each animal will be assured (where possible) in accordance with Covance SOPs. All procedures with cynomolgus monkey are in compliance with the Animal Welfare Act Regulations (9 CFR 3).

Acknowledgments
He Wang, Amy Lin and Yuwei Qian for protein generation. Josef Heuer for GEC-NFκB-luc cell-line generation and Veavi Ching-Yun Chang for statistical support. Dinorath Pamela Olvera Ramos and Garreth Lawrence for medical writing and editorial support.

Funding
Eli Lilly and Company (no grant numbers apply).

Disclosure
A. J. Okragly, K. B. Corwin, T. Shiyanova, M. Elia, Q. Zhang, D. He, S. B. Dicker, L. Chlewicki, O. Schroeder, S. M. E. Truhlar, J. Davies, C. N. Patel, and R. J. Benschop are employees of Eli Lilly and Company. Ms. Angela J Okragly, Dr. Chetan N Patel, Dr Stephanie ME Truhlar, Dr Julian Davies, and Dr Robert J Benschop have a patent US10501536B2 issued to Eli Lilly and Co. The authors report no other conflicts of interest in this work.

References
1. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. *Immunity.* 2005;23(5):479–490. doi:10.1016/j.immuni.2005.09.015
2. Mousson C, Ortega N, Girard J-P. The IL-1-Like Cytokine IL-33 Is Constitutively Expressed in the Nucleus of Endothelial Cells and Epithelial Cells In Vivo: a Novel ‘Alarmin’? *PLoS One.* 2008;3(10):e3331. doi:10.1371/journal.pone.0003331
3. Liew FY, Pitman NJ, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. *Nat Rev Immunol.* 2010;10(2):103–110. doi:10.1038/nri2692
4. Caylor C, Girard J-P. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. *Immunol Rev.* 2018;281(1):154–168. doi:10.1111/imr.12619
5. Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. *Proc Natl Acad Sci U S A.* 2007;104(1):282–287. doi:10.1073/pnas.0606854104
6. Roussel L, Erard M, Caylor C, Girard JP. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. *EMBO Rep.* 2008;9(10):1006–1012. doi:10.1038/embr.2008.145
7. Lefrancais E, Roga S, Gautier V, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathespisin G. *Proc Natl Acad Sci U S A.* 2012;109(5):1673–1678. doi:10.1073/pnas.1115884109
8. Lefrançais E, Duval A, Mirey E, et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci U S A. 2014;111(43):15502–15507. doi:10.1073/pnas.1407001111
9. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007;179(4):2551–2555. doi:10.4049/jimmunol.179.4.2551
10. Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol. 2011;7(6):321–329. doi:10.1038/nrrheum.2011.53
11. Yang Q, Li G, Zhu Y, et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol. 2011;41(11):3351–3360. doi:10.1002/eji.201141629
12. Suzuki M, Ikura M, Koketsu R, et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 Receptor. J Immunol. 2008;181(9):5981–5989. doi:10.4049/jimmunol.181.9.5981
13. Pushparaj PN, Tay HK, H'ng SC, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Nat Acad Sci. 2009;106(24):9773–9778. doi:10.1073/pnas.0901206106
14. Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol. 2010;185(6):3472–3480. doi:10.4049/jimmunol.1000730
15. Koyasu S, Moro K. Innate Th2-type immune responses and the IL-33 receptor complex. Curr Opin Allergy Clin Immunol. 2011;2(2):109–114. doi:10.1097/ACI.0b013e23283448808
16. Chang YJ, Kim HY, Albacker LA, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 2011;12(7):631–638. doi:10.1038/ni.2045
17. Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Chang Y, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. 2009;123(5):1047–1054. doi:10.1016/j.jaci.2009.02.026
18. Drake LY, Prakash YS. Contributions of IL-33 in non-hematopoietic lung cells to obstructive lung disease. Front Immunol. 2020;2:11.
19. Hsu CL, Neilsen CV, Bryce PJ. IL-33 is produced by mast cells and macrophages. Curr Opin Allergy Clin Immunol. 2010;20(1):16–26. doi:10.1006/cimm.2000.1617
20. Kondo Y, Yoshimoto T, Yasuda K, et al. IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci U S A. 2011;108(43):18581–18586. doi:10.1073/pnas.100359107
21. Tamari M, Hirota T. Genome-wide association studies of atopic dermatitis. J Dermatol. 2009;36(3):213–220. doi:10.1111/j.1346-8138.2009.813231
22. Li J, Zhang Y, Zhang L. Discovering susceptibility genes for allergic rhinitis and allergy using a genome-wide association study strategy. Curr Opin Allergy Clin Immunol. 2015;15(1):33–40. doi:10.1097/ACI.0000000000000124
23. Imai Y. Interleukin-33 in atopic dermatitis. J Dermatol. 2019;46(3):213–220. doi:10.1111/1346-8138.13231
24. Morita H, Nakae S, Saito H, Matsumoto K. IL-33 in clinical practice: size matters? J Immunol. 2016;197(2):381–383. doi:10.4049/jimmunol.1600499
25. Ober C, Nicolae DL. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. J Allergy Clin Immunol. 2011;128(9):1398–1410. doi:10.1016/j.jaci.2009.08.009
26. Dowsett DJ, Sorsa MA. Interleukin-33 in asthma and COPD. Curr Opin Allergy Clin Immunol. 2016;16(2):171–176. doi:10.1097/ACI.0000000000000234
27. Okayama H, Nishino H, Kato T, et al. Interleukin-33 regulates airway hyperresponsiveness in asthma. J Immunol. 2012;188(2):755–762. doi:10.4049/jimmunol.1103391
28. Ogawa Y, Sato H, Sato H, et al. IL-33 in non-respiratory diseases and its role in innate immunity. J Dermatol. 2020;47(4):236–244. doi:10.1111/1346-8138.15014
29. Wang E, Wang H, Shi H, et al. IL-33 regulates the development of human mast cells. Mol Immunol. 2018;98:271–278. doi:10.1016/j.molimm.2017.12.015
30. Koyasu S, Moro K. Innate Th2-type immune responses and the IL-33 receptor complex. Curr Opin Allergy Clin Immunol. 2011;11(2):109–114. doi:10.1097/ACI.0b013e23283448808
31. Chang YJ, Kim HY, Albacker LA, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 2011;12(7):631–638. doi:10.1038/ni.2045
32. Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Chang Y, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. 2009;123(5):1047–1054. doi:10.1016/j.jaci.2009.02.026
33. Drake LY, Prakash YS. Contributions of IL-33 in non-hematopoietic lung cells to obstructive lung disease. Front Immunol. 2020;2:11.
34. Hsu CL, Neilsen CV, Bryce PJ. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One. 2010;5(8):e11944. doi:10.1371/journal.pone.0011944
35. Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol. 2008;20(6):791–800. doi:10.1093/intimm/dxn037
36. Izhara K, Ohta S, Shiraihi H, et al. The mechanism of mucus production in bronchial asthma. Curr Med Chem. 2009;16(22):2867–2875. doi:10.2174/092986709788803196
37. Boguniewicz M, Leung DYM. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233–246. doi:10.1111/j.1600-065X.2011.01207.x
38. Imam Y. Interleukin-33 in atopic dermatitis. J Dermatol Sci. 2019;96(1):2–7. doi:10.1016/j.jdermsci.2019.08.006
39. Savenije OE, Mahachie John JM, Granell R, et al. Association of IL-33–IL-1 receptor–like 1 (IL1RL1) pathway polymorphisms with wheeze phenotypes and asthma in childhood. J Allergy Clin Immunol. 2014;134(1):170–177.
40. Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010;363(13):1211–1221. doi:10.1056/NEJMoa0906312
41. Ober C, Nicolae DL. Meta-analysis of genomewide association studies of asthma in ethnically diverse North American populations. Nat Genet. 2011;43(9):887–892. doi:10.1038/ng.888
42. Tamari M, Hirota T. Genome-wide association studies of atopic dermatitis. J Dermatol. 2014;41(3):213–220. doi:10.1111/1346-8138.13231
45. Consortium TU. UniProt: a hub for protein information. Nucleic Acids Res. 2014;43(D1):D204–D212.
46. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010;10(2):103–110.
47. Mueller T, Dieplinger B. The Presage ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn. 2013;13(1):13–30. doi:10.1586/erm.12.128
48. Schwartz C, O’Grady K, Lavelle EC, Fallon PG. Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer. Eur J Immunol. 2016;46(5):1091–1100. doi:10.1002/eji.201545780.
49. Latiano A, Palmieri O, Pastorelli L, et al. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One. 2013;8(4):e62144. doi:10.1371/journal.pone.0062144
50. Sun BB, Ma LJ, Qi Y, Zhang GJ. Correlation of IL-33 gene polymorphism with chronic obstructive pulmonary disease. Eur Rev Med Pharmacol Sci. 2019;23(14):6277–6282.
51. Koca SS, Pehlivan Y, Kara M, et al. The IL-33 gene is related to increased susceptibility to systemic sclerosis. Rheumatol Int. 2016;36(4):579–584. doi:10.1007/s00296-015-3417-8
52. Li C, Ma R, Guo J, et al. Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis. Arthritis Res Ther. 2014;16(2):R105. doi:10.1186/ar4554
53. Guo J, Xiang Y, Peng Y-F, Huang H-T, Lan Y, Wei Y-S. The association of novel IL-33 polymorphisms with sIL-33 and risk of systemic lupus erythematosus. Mol Immunol. 2016;77:1–7. doi:10.1016/j.molimm.2016.07.001
54. Xu W, Liu Y, Ye D. Association between IL-33 Gene Polymorphisms (rs1929992, rs7044343) and Systemic Lupus Erythematosus in a Chinese Han Population. Immunol Invest. 2016;45(7):575–583. doi:10.1080/08820139.2016.1193868